K6S.F MIRA Pharmaceuticals, Inc.

Healthcare Drug Manufacturers - General Frankfurt Exchange
0.5460 EUR
Close of Nov 12, 2026
0.4458 1.33
Market cap
EUR 22.9M
P/E
-
P/B
3.06x
ROE
-57.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is K6S.F undervalued?

Graham number

The Graham number of MIRA Pharmaceuticals, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MIRA Pharmaceuticals, Inc. fundamental analysis

No fundamental analysis for MIRA Pharmaceuticals, Inc. yet.

MIRA Pharmaceuticals, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering fr…

Full company profile